[EN] PYRAZOLO[3,4-D]PYRIMIDIN DERIVATIVE AND ITS USE FOR THE TREATMENT OF LEISHMANIASIS [FR] DÉRIVÉ DE PYRAZOLO [3,4-D] PYRIMIDINE ET SON UTILISATION POUR LE TRAITEMENT DE LA LEISHMANIOSE
A practical and sustainable method for the synthesis of levocabastine hydrochloride (1), a H₁ receptorantagonist for the treatment of allergic conjunctivitis, that can be applied to the industrial production of the compound has been developed. Substantial improvements over the previously reported procedure are achieved via efficient preparation of an optically active key intermediate (5) without chiral
Novel, Orally Bioavailable γ-Aminoamide CC Chemokine Receptor 2 (CCR2) Antagonists
作者:Alexander Pasternak、Dominick Marino、Pasquale P. Vicario、Julia Marie Ayala、Margaret A. Cascierri、William Parsons、Sander G. Mills、Malcolm MacCoss、Lihu Yang
DOI:10.1021/jm060439n
日期:2006.8.1
Through modification of a screening hit we have discovered a structurally distinct new lead, (2S)-N-[3,5-bis(trifluoromethyl)benzyl]-2-(4-fluorophenyl)-4-(4-phenylpiperidin-1-yl)butanamide (11), which has subsequently served as the departure point for an ongoing program targeting CCR2 antagonists. Optimization of 11 leading to antagonists 26 and 37 is described. Antagonist 26 was shown to have good oral bioavailability in rats. Antagonist 37 had a CCR2 IC50 of 59 nM and excellent potency in a functional assay measuring inhibition of MCP-1 induced monocyte chemotaxis (IC50 of 41 nM).